Codi QR

Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19

Small molecule drugs promise to remain a valuable tool in controlling the ongoing COVID-19 pandemic. Here the authors describe optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for potential treatment of COVID-19.

Guardat en:
Autors principals: Hengrui Liu, Sho Iketani, Arie Zask, Nisha Khanizeman, Eva Bednarova, Farhad Forouhar, Brandon Fowler, Seo Jung Hong, Hiroshi Mohri, Manoj S. Nair, Yaoxing Huang, Nicholas E. S. Tay, Sumin Lee, Charles Karan, Samuel J. Resnick, Colette Quinn, Wenjing Li, Henry Shion, Xin Xia, Jacob D. Daniels, Michelle Bartolo-Cruz, Marcelo Farina, Presha Rajbhandari, Christopher Jurtschenko, Matthew A. Lauber, Thomas McDonald, Michael E. Stokes, Brett L. Hurst, Tomislav Rovis, Alejandro Chavez, David D. Ho, Brent R. Stockwell
Format: Artigo
Idioma:Inglês
Publicat: Nature Portfolio 2022-04-01
Col·lecció:Nature Communications
Accés en línia:https://doi.org/10.1038/s41467-022-29413-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars